Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2021 | Pyrvinium | Research

Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer

Author: Yitian Li

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

Anaplastic thyroid carcinoma is a highly lethal subtype of thyroid cancer without effective therapies. Drug resistance in anaplastic thyroid carcinoma poses a significant problem. Although artemisinin exerts antitumor effects, but its efficacy in anaplastic thyroid carcinoma is unknown.

Methods

We used RNA sequencing to identify differentially expressed genes. Next, we determined the cause of ART resistance by testing the expression and activity of β-catenin, and enhanced ART activity with a WNT signaling inhibitor.

Results

Artemisinin suppressed the growth of BHT-101 but not human thyroid anaplastic carcinoma (CAL-62) cells. The mechanism of artemisinin resistance in CAL-62 was associated with the aberrant activation of WNT signaling. Pyrvinium pamoate, an inhibitor of WNT signaling, was used to overcome ART resistance in CAL-62 cells. The combination of artemisinin and pyrvinium pamoate suppressed the growth of CAL-62 cells and induced the apoptosis.

Conclusions

Our study is the first to prove the efficacy of ART as monotherapy or in combination with PP in the management of anaplastic thyroid cancer, and that the inhibition of WNT signaling may overcome ART resistance.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRef

Ma M, Lin B, Wang M, Liang X, Su L, Okose O, et al. Immunotherapy in anaplastic thyroid cancer. Am J Transl Res. 2020;12(3):974–88.PubMedPubMedCentral

Fallahi P, Ruffilli I, Elia G, Ragusa F, Ulisse S, Baldini E, et al. Novel treatment options for anaplastic thyroid cancer. Expert Rev Endocrinol Metab. 2017;12(4):279–88. https://doi.org/10.1080/17446651.2017.1340155.CrossRefPubMed

Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, et al. BRAF inhibition in BRAFV600E-positive anaplastic thyroid carcinoma. J Natl Compr Cancer Netw. 2016;14(3):249–54. https://doi.org/10.6004/jnccn.2016.0030.CrossRef

Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito K, et al. The safety and efficacy of weekly paclitaxel Administration for Anaplastic Thyroid Cancer Patients: a Nationwide prospective study. Thyroid. 2016;26(9):1293–9. https://doi.org/10.1089/thy.2016.0072.CrossRefPubMed

Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer. 2005;92(6):1110–6. https://doi.org/10.1038/sj.bjc.6602461.CrossRefPubMedPubMedCentral

Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7(13):17194–211. https://doi.org/10.18632/oncotarget.7839.CrossRefPubMedPubMedCentral

Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146(6):855–8. https://doi.org/10.1016/j.cell.2011.08.024.CrossRefPubMedPubMedCentral

10.

Chen GQ, Benthani FA, Wu J, Liang D, Bian ZX, Jiang X. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 2020;27(1):242–54. https://doi.org/10.1038/s41418-019-0352-3.CrossRefPubMed

11.

Wang X, Meng K, Wang Y, Zhao Y, Lin F, Liu X, et al. Wilms' tumor (WT1) (+/−KTS) variants decreases the progesterone secretion of bovine ovarian theca cells. Domest Anim Endocrinol. 2021;74:106521. https://doi.org/10.1016/j.domaniend.2020.106521.CrossRefPubMed

12.

Li YT, Tian XT, Wu ML, Zheng X, Kong QY, Cheng XX, et al. Resveratrol suppresses the growth and enhances retinoic acid sensitivity of anaplastic thyroid cancer cells. Int J Mol Sci. 2018;19(4):1030.CrossRef

13.

Yang L, Sun R, Wang Y, Fu Y, Zhang Y, Zheng Z, et al. Expression of ANGPTL2 and its impact on papillary thyroid cancer. Cancer Cell Int. 2019;19(1):204. https://doi.org/10.1186/s12935-019-0908-9.CrossRefPubMedPubMedCentral

14.

Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019;38(35):6241–55. https://doi.org/10.1038/s41388-019-0873-8.CrossRefPubMedPubMedCentral

15.

Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–5. https://doi.org/10.1002/cncr.20936.CrossRefPubMed

16.

Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895–9. https://doi.org/10.1158/1078-0432.CCR-07-2248.CrossRefPubMed

17.

Chen J, Liu TY, Peng HT, Wu YQ, Zhang LL, Lin XH, et al. Up-regulation of Wnt7b rather than Wnt1, Wnt7a, and Wnt9a indicates poor prognosis in breast cancer. Int J Clin Exp Pathol. 2018;11(9):4552–61.PubMedPubMedCentral

18.

Li Q, Ye L, Zhang X, Wang M, Lin C, Huang S, et al. FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling. Cancer Lett. 2017;402:166–76. https://doi.org/10.1016/j.canlet.2017.05.029.CrossRefPubMed

19.

Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–73. https://doi.org/10.1038/onc.2016.304.CrossRefPubMed

20.

Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109(8):djw332.CrossRef

21.

Momtazi-Borojeni AA, Abdollahi E, Ghasemi F, Caraglia M, Sahebkar A. The novel role of pyrvinium in cancer therapy. J Cell Physiol. 2018;233(4):2871–81. https://doi.org/10.1002/jcp.26006.CrossRefPubMed

Title: Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer
Author: Yitian Li
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pyrvinium
Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03332-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

A mixed-methods survey of physiotherapists who practice acupuncture and dry needling in Ontario, Canada: practice characteristics, motivations, and professional outcomes

Antiplasmodial activity of Ethanolic extract of Cassia spectabilis DC leaf and its inhibition effect in Heme detoxification

Efficacy of Euphorbia helioscopia in context to a possible connection between antioxidant and antidiabetic activities: a comparative study of different extracts

Protective effect of Glechoma hederacea extract against gallstone formation in rodent models

The effectiveness and safety of Tai Chi for patients with essential hypertension: study protocol for an open-label single-center randomized controlled trial

Effect of cranberry supplementation on liver enzymes and cardiometabolic risk factors in patients with NAFLD: a randomized clinical trial